scholarly journals 500: SLEEP DISTURBANCES IN INFANTS AND YOUNG CHILDREN FOLLOWING CRITICAL CARE FOR ACQUIRED BRAIN INJURY

2021 ◽  
Vol 50 (1) ◽  
pp. 241-241
Author(s):  
Jamie Klapp ◽  
Trevor Hall ◽  
Julie Randall ◽  
Cydni Williams
SLEEP ◽  
2021 ◽  
Vol 44 (Supplement_2) ◽  
pp. A233-A233
Author(s):  
Cydni Williams ◽  
Miranda Lim ◽  
Cindy McEovy ◽  
Trevor Hall ◽  
Kurt Drury ◽  
...  

Abstract Introduction Annually, over 60,000 children require critical care admission for acquired brain injury (ABI) in the US, and many face long-term cognitive morbidity. Over 50% of these children also develop sleep/wake disturbances (SWD). Given the importance of sleep to brain development and healing after injury, we hypothesized SWD in children after ABI would portend worse cognitive outcomes in domains of executive function. Methods We performed a prospective observational study of N=80 children aged 6–18 years with ABI evaluated 1–3 months after critical care hospitalization. SWD were evaluated using the Sleep Disturbances Scale for Children (SDSC). The primary outcome was the Behavior Rating Inventory of Executive Function, 2nd Edition (BRIEF-2) Global Executive Composite (GEC; an age and gender adjusted T-score). Secondary cognitive outcomes included age adjusted scaled scores (ss) from the Delis Kaplan Executive Function System (DKEFS), Wechsler Intelligence Scale for Children, 5th Edition (WISC-V), and Children’s Memory Scale (CMS). Relationships between the SDSC and cognitive measures were evaluated using Spearman correlation (rs). Multiple linear regression evaluated associations between SWD and GEC T-scores controlling for patient and ABI characteristics. Results Sixty-five (81%) eligible children completed evaluation, and 48% had clinically significant SWD (total SDSC ≥39). Significant correlation (p<0.05) was found between the SDSC total score and worse GEC T-score (rs=0.60), and worse ss for CMS numbers forward (rs= -0.39), WISC-V coding (rs=-0.36), DKEFS number letter switching total time (rs=-0.38), and DKEFS category fluency (rs=-0.43). Presence of SWD was significantly associated with a full standard deviation worsening in the GEC T-score (β-coefficient= 10.2, 95% Confidence Interval=1.0–19.3) when controlling for age, race, gender, admission Glasgow Coma Scale, critical care intervention, and chronic comorbidities. Conclusion Children with ABI requiring critical care have high rates of SWD after discharge that are associated with significantly worse executive function outcomes in overall function (BRIEF-2 GEC) and direct objective assessments (DKEFS, WISC-V, CMS) evaluating aspects of executive functioning including attention, processing speed, cognitive flexibility, and working memory. SWD may serve as a modifiable target to improve cognitive outcomes in this vulnerable pediatric population. Support (if any) This work is supported by the National Heart Lung and Blood Institute (K23HL150229-01)


2019 ◽  
Vol 20 (11) ◽  
pp. 1061-1068
Author(s):  
Corina Noje ◽  
Eric M. Jackson ◽  
Isam W. Nasr ◽  
Philomena M. Costabile ◽  
Marcelo Cerullo ◽  
...  

2006 ◽  
Vol 130 (5) ◽  
pp. 712-717 ◽  
Author(s):  
David Dolinak ◽  
Ross Reichard

Abstract Context.—Inflicted traumatic brain injury of infants and young children results in a complex array of autopsy findings. In many cases, immunostains for β-amyloid precursor protein are used to detect axonal injury. Interpretation of the gross, microscopic, and immunostaining results requires the integration of the many facets of the individual case. Objective.—In this article we review the gross and microscopic findings associated with inflicted traumatic brain injury. The application and interpretation of β-amyloid precursor protein immunostains are discussed and photomicrographs are used to illustrate immunostaining patterns. Data Sources.—The pertinent literature is integrated into a review of the subject. Conclusions.—Inflicted traumatic brain injury often results in subdural, subarachnoid, retinal, and optic nerve sheath hemorrhage. These findings must be interpreted within the entire context of the case. β-Amyloid precursor protein immunostains may be helpful in illustrating the traumatic nature of the injuries in some cases.


2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Réjean M. Guerriero ◽  
Michael J. Morrissey ◽  
Maren Loe ◽  
Joseph Reznikov ◽  
Michael M. Binkley ◽  
...  

2020 ◽  
Vol 40 (3) ◽  
pp. e9-e16 ◽  
Author(s):  
Elizabeth A. Shald ◽  
Jacob Reeder ◽  
Michael Finnick ◽  
Ishani Patel ◽  
Kyle Evans ◽  
...  

Background Paroxysmal sympathetic hyperactivity, which affects up to 10% of all acquired brain injury survivors, is characterized by elevated heart rate, blood pressure, respiratory rate, and temperature; diaphoresis; and increased posturing. Pharmacological agents that have been studied in the management of this disorder include opiates, γ-aminobutyric acid agents, dopaminergic agents, and β blockers. Although paroxysmal sympathetic hyperactivity is a relatively common complication after acquired brain injury, there is a paucity of recommendations or comparisons of agents for the management of this disorder. Objective To evaluate all relevant literature on pharmacological therapies used to manage patients with paroxysmal sympathetic hyperactivity to help elucidate possible best practices. Methods Of the 27 studies evaluated for inclusion, 10 studies received full review: 4 retrospective cohort studies, 5 single case studies, and 1 case series. Results Monotherapy is usually not effective in the management of paroxysmal sympathetic hyperactivity and multiple agents with different mechanisms of action should be considered. α2-Agonists such as dexmedetomidine may hold some slight clinical efficacy over agents like propofol, and with respect to oral medications, propranolol might convey some slight advantage compared to others. However, with the limited data available, these results must be interpreted with caution. Conclusions As the treatment of paroxysmal sympathetic hyperactivity is reactive to symptomatic evolution over time, critical care nurses play a vital role in the monitoring and treatment of these patients. Limited data exist on the management of paroxysmal sympathetic hyperactivity and larger robust data sets are needed to guide decision-making. (Critical Care Nurse. 2020;40[3]:e9-e16)


Author(s):  
Cydni N. Williams ◽  
Mary E. Hartman ◽  
Kristin P. Guilliams ◽  
Rejean M. Guerriero ◽  
Juan A. Piantino ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document